Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
NCT05929716 · M.D. Anderson Cancer Center · PHASE2 · withdrawn · last registry update 2023-11-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Per Principal Investigator request” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD47 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-02Results posted on the registry: Astex Pharmaceuticals, Inc., Decitabine/Cedazuridine + Magrolimab (NCT05835011)
- 2024-10-02Also stopped (terminated): Astex Pharmaceuticals, Inc., Decitabine/Cedazuridine + Magrolimab (NCT05835011)
- 2024-09-19Also stopped (withdrawn): City of Hope Medical Center, Azacitidine + Magrolimab (NCT05823480)
- 2024-07-05Also stopped (withdrawn): Insel Gruppe AG, University Hospital Bern, Magrolimab + Cisplatin (NCT05738161)
- 2024-06-27Also stopped (terminated): Gilead Sciences, Magrolimab + Azacitidine (NCT04313881)
- 2024-05-02Also stopped (withdrawn): National Cancer Institute (NCI), Magrolimab + Olaparib (NCT05807126)
- 2024-04-11Also stopped (withdrawn): Novartis Pharmaceuticals, Sabatolimab + Magrolimab (NCT05367401)
- 2024-04-01Results posted on the registry: Gilead Sciences, Magrolimab + Avelumab (NCT03558139)
- 2024-03-21Results posted on the registry: Gilead Sciences, Magrolimab + Azacitidine (NCT04313881)
- 2024-02-12Also stopped (withdrawn): Uwe Platzbecker, Magrolimab + 7+3 (NCT05829434)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision